Oxygenta Pharmaceutical Ltd. (OXYGENTAPH): Oxygenta Pharmaceutical Share Price Rises 20% as Stock Enters Top Gainers Today

Oxygenta Pharmaceutical Ltd. rose 20% to Rs 65.64 today, taking its market capitalisation to Rs 202.30 crore and placing the micro-cap stock among notable BSE gainers.

Oxygenta Pharmaceutical Share Price moved sharply higher on 11 August 2026, with the stock trading at Rs 65.64, up 20% for the day, lifting the company’s market capitalisation to Rs 202.30 crore. In Stock Market Today activity, that made the pharmaceutical micro cap one of the more visible market movers on the BSE, especially because the stock touched its intraday high at the same level as the current price.

The verified data confirms a strong same-day price rise, but it does not establish a company-specific catalyst behind the move. That distinction matters. For investors scanning Oxygenta Pharmaceutical Stock News or searching Oxygenta Pharmaceutical Share Price Today, the key takeaway is that the price action itself was significant enough to clear the bar for its Micro Cap category and to place the stock in the day’s top-gainer conversation.

The move also came with Rs 0.23 crore in turnover and 34,426 shares in BSE volume, showing active participation relative to the stock’s usual micro-cap profile, even though the supplied dataset does not link the move to earnings, a filing, or other corporate trigger. Univest notes that when a stock records a qualifying one-day jump without a verified cause in the supplied data, the focus shifts to price structure, valuation context, sector standing and peer comparison rather than speculation.

For readers tracking Oxygenta Pharmaceutical Share Price, the immediate questions are straightforward: what happened in today’s trade, how does the valuation compare with the Pharmaceuticals & Drugs industry, and what should investors monitor next? This Univest analysis addresses those points using only the verified numbers supplied for the stock, its sector benchmark and listed peers.

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 65.64
Previous Close	Rs 54.7
Today's Change	+Rs 10.94 (+20%)
Day Open	Rs 58.8
Day High	Rs 65.64
Day Low	Rs 54.75
Current Volume (BSE)	34,426
BSE Traded Volume	34,426
Combined NSE + BSE Volume	34,426
Turnover	Rs 0.23 crore
Market Capitalisation	Rs 202.3 crore
Market Cap Category	Micro Cap

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) traded at Rs 65.64. versus the previous close of Rs 54.7, a rise of 20%. The stock opened at Rs 58.8, reached Rs 65.64, touched Rs 54.75. Reported volume was 34,426.

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 202.3 crore
P/E Ratio	-17.89x
P/B Ratio	-4.52x
ROE	0%
ROCE	3.18%
EPS	Rs -3.67
Dividend Yield	0%

Oxygenta Pharmaceutical Ltd. was valued at a P/E ratio of -17.89x, a P/B ratio of -4.52x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 0% and ROCE of 3.18%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs -3.67, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Oxygenta Pharmaceutical Fundamental Analysis begins with its size and valuation profile. The company’s market capitalisation stands at Rs 202.30 crore, placing it in the micro-cap segment where price moves can become pronounced even on modest turnover. On valuation, the stock is trading at a P/E ratio of -17.89 and a P/B ratio of -4.52. Negative valuation multiples are important in financial analysis because they usually indicate that conventional earnings or net-worth comparisons are not presenting the business in the same way as profitable, balance-sheet-positive peers.

The profitability figures reinforce that point. Return on equity is 0, while ROCE is 3.18%. ROE at 0 suggests that the business is not currently generating a meaningful return on shareholder equity based on the supplied snapshot, and the 3.18% ROCE indicates relatively low returns on capital employed compared with stronger operators in the broader listed pharmaceuticals space. For investors looking at Oxygenta Pharmaceutical Financial Results context through market ratios alone, those numbers suggest that the current investor attention is being driven more by price action than by a high-profitability profile.

EPS is -3.67, which means earnings attributable to each share are negative on the supplied data. That helps explain the negative P/E ratio. Dividend yield is 0, indicating there is no current historical payout yield reflected in this dataset relative to the present stock price. These are useful anchors because they tell investors that the stock’s current appeal in today’s trade is not coming from an income angle, and the earnings base remains under pressure.

At the same time, market capitalisation is still above the industry median market cap of Rs 146.99 crore within the same benchmark set, which means Oxygenta is not among the smallest names in its industry sample even though it remains a micro cap. Univest would therefore frame the setup as a stock where the share price rise is clear and measurable, but the fundamental profile remains mixed to weak on profitability and valuation-quality indicators. That makes the sector and peer comparison especially important before drawing broader conclusions from a single session’s move.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	-17.89x
Benchmark Median P/E	25.7x
Benchmark Average P/E	69.27x
Benchmark P/E Range	3.08x to 3,396.3x
Company P/B Ratio	-4.52x
Benchmark Median P/B	1.8x
Company ROE	0%
Benchmark Median ROE	10.59%
Company ROCE	3.18%
Benchmark Median ROCE	12.98%
Company Market Capitalisation	Rs 202.3 crore
Benchmark Median Market Cap	Rs 146.99 crore

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) has a P/E ratio of -17.89x, which is below the benchmark median of 25.7x, a difference of -169.61%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) has a ROE of 0%, which is below the benchmark median of 10.59%, a difference of -100%. Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) has a ROCE of 3.18%, which is below the benchmark median of 12.98%, a difference of -75.5%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Oxygenta Pharmaceutical operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied benchmark covers the same industry and includes 137 companies, making it a useful reference point for judging whether today’s market attention is occurring against a stronger or weaker fundamental backdrop than the broader listed peer set.

Start with valuation. Oxygenta’s company P/E is -17.89, while the benchmark median P/E is 25.70 and the benchmark average is 69.27 across 104 companies with P/E data. The industry P/E range runs from 3.08 to 3,396.30. On a strict numerical basis, Oxygenta sits below both the median and the average because its P/E is negative. That means the stock is not currently comparable with profit-making names that populate the positive side of the sector multiple range.

The same pattern appears in price-to-book. Oxygenta’s P/B is -4.52 versus an industry median of 1.80 and an average of 2.49 across 136 companies, with a range from -16.90 to 15.98. Again, the company’s ratio is below the benchmark median and average numerically. In profitability terms, company ROE is 0 compared with a benchmark median of 10.59 and average of 8.24, while ROCE is 3.18 against an industry median of 12.98 and average of 15.72. Those numbers place Oxygenta below the sector’s central tendency on returns.

On size, however, the comparison is more balanced. Oxygenta’s market cap of Rs 202.30 crore is above the industry median of Rs 146.99 crore, though well below the average of Rs 500.01 crore and far below the upper end of Rs 3,032.97 crore. That means the company is larger than many smaller industry constituents but still materially below the better-known listed pharma names in the benchmark set. From a Univest sector-analysis standpoint, today’s price rise stands out more than the company’s current relative valuation and return metrics do.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	3,032.97	0	0.76	-2.89	-0.26
Hikal Ltd.	HIKAL	2,799.54	0	2.32	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,707.2	40.09	9.77	28.21	26.35
Beta Drugs Ltd.	BETA	2,631.45	66.92	10.59	18.65	22.17
Panacea Biotec Ltd.	PANACEABIO	2,531.49	0	8.67	0	5.36

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) has a P/E ratio of -17.89x compared with the displayed peer median of 0x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 0% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 3.18% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) has a market capitalisation of Rs 202.3 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Oxygenta Pharmaceutical Share Price is drawing attention in part because peer data shows how different its present fundamental profile is from several other listed Pharmaceuticals & Drugs names. The supplied peer set includes companies such as Hikal Ltd., Kwality Pharmaceuticals Ltd., Beta Drugs Ltd., Panacea Biotec Ltd., Sai Parenteral's Ltd., NGL Fine-Chem Ltd., Venus Remedies Ltd. and Hester Biosciences Ltd., with market capitalisations ranging from Rs 2,057.85 crore to Rs 3,032.97 crore among the highlighted names. That alone shows Oxygenta’s Rs 202.30 crore market cap is far smaller than the peer sample inserted by the workflow.

On valuation, Oxygenta’s negative P/E of -17.89 contrasts with positive P/E readings for several peers, including Kwality Pharmaceuticals at 40.09, Beta Drugs at 66.92, Sai Parenteral's at 181.97, NGL Fine-Chem at 44.48, Venus Remedies at 17.49 and Hester Biosciences at 15.63. The peer data therefore suggests that a number of comparable listed companies are trading on positive earnings multiples, while Oxygenta remains in a loss-linked valuation position.

Profitability comparisons point in the same direction. Oxygenta’s ROCE of 3.18 is below Hikal’s 16.15, Kwality’s 26.35, Beta Drugs’ 22.17, Sai Parenteral's 12.97, NGL Fine-Chem’s 33.91 and Hester Biosciences’ 14.12. Even Panacea Biotec, which has ROE of 0 like Oxygenta, posts a higher ROCE of 5.36. On price-to-book, Oxygenta’s -4.52 sits below peer P/B figures such as Hikal’s 2.32, Kwality’s 9.77, Beta Drugs’ 10.59, Venus Remedies’ 2.96 and Hester Biosciences’ 4.68.

That does not explain today’s price rise by itself, but it does show that the stock’s current market attention is occurring despite weaker relative profitability and unusual negative valuation readings versus much larger peers. For readers seeking Oxygenta Pharmaceutical Stock Analysis, the peer view adds important balance to the day’s strong price action.

Why Investors Are Watching Oxygenta Pharmaceutical

Today’s move has placed Oxygenta Pharmaceutical Ltd. on the radar because the share price gain was large enough to stand out even within a busy Share Market Today session. The stock rose 20% to Rs 65.64, traded across a wide intraday range and qualified under the Micro Cap price-rise event screen. With no verified company-specific trigger in the supplied data, investors are watching the numbers that can actually be confirmed.

• Verified price action: The stock rose Rs 10.94 from the previous close of Rs 54.70 to Rs 65.64.
• Intraday structure: It opened at Rs 58.80, touched a low of Rs 54.75 and climbed to a high of Rs 65.64.
• Liquidity snapshot: BSE volume stood at 34,426 shares with turnover of Rs 0.23 crore.
• Fundamental context: P/E is -17.89, P/B is -4.52, ROE is 0, ROCE is 3.18 and EPS is -3.67.
• Sector positioning: The stock sits in Healthcare, Pharmaceuticals & Drugs, with return metrics below industry medians.

What should investors monitor next? The most relevant points are whether Oxygenta Pharmaceutical Share Price can hold above the session’s sharp gain zone, whether follow-through volume remains visible, and whether future Oxygenta Pharmaceutical Latest News or Oxygenta Pharmaceutical Earnings disclosures provide a clearer business explanation than price action alone. Univest sees this as a data-led watchlist situation rather than a conclusion-driven one.

About Oxygenta Pharmaceutical

Oxygenta Pharmaceutical Ltd. is classified in the Healthcare sector and specifically within the Pharmaceuticals & Drugs industry. That places it in one of the most closely tracked segments of the Indian Stock Market, where investors often monitor listed companies through a mix of valuation ratios, return metrics, market capitalisation and Stock Performance screens.

Based on the supplied company context, the most reliable way to understand Oxygenta is through its industry placement rather than through unsupported business-detail assumptions. It is part of the pharmaceuticals and drugs ecosystem, which means its listed comparisons in the provided benchmark include companies engaged across broader healthcare manufacturing and drug-related operations. The benchmark itself spans 137 same-industry companies, showing that Oxygenta operates in a deep and varied listed universe.

At Rs 202.30 crore in market capitalisation, the company is larger than the industry median of Rs 146.99 crore but substantially smaller than the upper tier of listed pharma names in the provided sample. That makes it relevant for investors who track smaller-cap healthcare counters on BSE and NSE screens, especially when they appear among Top Gainers Today. For readers using Univest for Oxygenta Pharmaceutical Company News or a market update, the essential company identity is clear: this is a micro-cap pharmaceuticals stock whose latest visibility comes from a strong one-day market move rather than from a stated corporate announcement in the supplied data.

Track Oxygenta Pharmaceutical Share Price on Univest

Use Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors who want to follow Oxygenta Pharmaceutical Share Price more closely can use Univest to track live Share Price movements, day highs and lows, market capitalisation changes and broader Stock Updates in one place. Univest also helps readers compare valuation ratios such as P/E and P/B, review profitability indicators including ROE and ROCE, and place a stock inside its sector and peer context.

For micro-cap counters, context matters as much as the headline move. That is why Oxygenta Pharmaceutical Share Price Today is best monitored alongside 52-week levels, company financial metrics, shareholding pattern when available, and fresh market insights as they are updated. For anyone following Oxygenta Pharmaceutical NSE or Oxygenta Pharmaceutical BSE activity, Univest offers a structured way to keep the day’s price rise connected to measurable data rather than speculation.

Frequently Asked Questions

Why is Oxygenta Pharmaceutical Share Price rising today?

Ans. Oxygenta Pharmaceutical Share Price rose because the stock gained 20% in the current session, moving from the previous close of Rs 54.70 to Rs 65.64. The supplied data confirms the price event, but it does not establish a company-specific catalyst.

What is Oxygenta Pharmaceutical Share Price Today?

Ans. Oxygenta Pharmaceutical Share Price Today is Rs 65.64 in the supplied market snapshot. The stock was up 20% on the day, after opening at Rs 58.80 and trading within an intraday range of Rs 54.75 to Rs 65.64.

How much did Oxygenta Pharmaceutical stock gain today?

Ans. The stock gained Rs 10.94 in absolute terms and rose 20% in percentage terms versus its previous close of Rs 54.70. That made Oxygenta Pharmaceutical one of the more noticeable top gainers within today’s micro-cap market action.

What is the market capitalisation of Oxygenta Pharmaceutical Ltd.?

Ans. Oxygenta Pharmaceutical Ltd. has a market capitalisation of Rs 202.30 crore based on the supplied data. That places the company in the Micro Cap category, which is relevant because today’s move qualified under that price-rise event screen.

What do today’s trading levels show for Oxygenta Pharmaceutical?

Ans. Today’s trading levels show a strong upward session. The stock opened at Rs 58.80, touched a low of Rs 54.75, and climbed to a high of Rs 65.64, which also matched the current traded price in the snapshot.

What was the trading volume in Oxygenta Pharmaceutical today?

Ans. Oxygenta Pharmaceutical recorded total volume of 34,426 shares, with the reported activity coming on the BSE. The session’s turnover stood at Rs 0.23 crore, confirming visible participation alongside the stock’s 20% same-day price rise.

Is Oxygenta Pharmaceutical profitable based on the supplied data?

Ans. The supplied profitability indicators look weak. EPS is -3.67, the P/E ratio is -17.89, ROE is 0, and ROCE is 3.18. Those figures suggest the stock’s current attention is driven more by price action than profitability strength.

How does Oxygenta Pharmaceutical compare with its industry benchmark?

Ans. Oxygenta Pharmaceutical’s P/E of -17.89 is below the industry median of 25.70 and average of 69.27. Its ROE of 0 and ROCE of 3.18 are also below the benchmark medians of 10.59 and 12.98 respectively.

How does Oxygenta Pharmaceutical compare with listed pharma peers?

Ans. Oxygenta Pharmaceutical is much smaller than the supplied peers, with a market cap of Rs 202.30 crore versus peer examples above Rs 2,000 crore. Its negative P/E and lower ROCE also compare unfavourably with several profit-making pharmaceutical peers.

What should investors monitor after today’s Oxygenta Pharmaceutical move?

Ans. Investors can monitor whether the stock sustains today’s sharp price rise, whether trading participation remains active after the 34,426-share session, and whether future company updates provide a clearer business explanation for the move than price action alone.